ERBB2 and breast cancer: This case illustrates a clinically important pattern of failure in contemporary HER2-positive breast cancer: despite pCR after neoadjuvant dual HER2 blockade and completion of 1 year of trastuzumab plus pertuzumab, the CNS became the first and only site of relapse.